Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Price & Analysis

1,006 Followers

JAZZ Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$125.35 - $163.31
Previous Close$128.91
Volume501.09K
Average Volume (3M)495.85K
Market Cap
$8.30B
Enterprise Value$12.94B
Total Cash (Recent Filing)$1.17B
Total Debt (Recent Filing)$5.80B
Price to Earnings (P/E)-48.8
Beta0.52
Aug 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding64,004,791
10 Day Avg. Volume704,783
30 Day Avg. Volume495,846
Standard Deviation0.09
R-Squared0.20
Alpha-0.00705
Financial Highlights & Ratios
Price to Book (P/B)-1.87
Price to Sales (P/S)9.24
Price to Cash Flow (P/CF)6.00
P/FCF Ratio5.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda23.15
Forecast
Price Target Upside58.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9


Financials

Annual

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.

---

JAZZ FAQ

What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $125.35 and its highest was $163.31 in the past 12 months.
    What is Jazz Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Jazz Pharmaceuticals’s upcoming earnings report date?
    Jazz Pharmaceuticals’s upcoming earnings report date is Aug 08, 2023 which is in 61 days.
      How were Jazz Pharmaceuticals’s earnings last quarter?
      Jazz Pharmaceuticals released its earnings results on May 10, 2023. The company reported $3.95 earnings per share for the quarter, missing the consensus estimate of $4.24 by -$0.29.
        Is Jazz Pharmaceuticals overvalued?
        According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Jazz Pharmaceuticals pay dividends?
          Jazz Pharmaceuticals does not currently pay dividends.
          What is Jazz Pharmaceuticals’s EPS estimate?
          Jazz Pharmaceuticals’s EPS estimate is $4.5.
            How many shares outstanding does Jazz Pharmaceuticals have?
            Jazz Pharmaceuticals has 64,004,790 shares outstanding.
              What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
              Jazz Pharmaceuticals reported an EPS of $3.95 in its last earnings report, missing expectations of $4.24. Following the earnings report the stock price went up 0.41%.
                Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
                Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 191M.

                  ---

                  Jazz Pharmaceuticals Stock Smart Score

                  The Jazz Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Jazz Pharmaceuticals

                  Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

                  ---

                  Top 5 ETFs holding JAZZ

                  Name
                  Market Value
                  Smart Score
                  Vanguard Health Care ETF
                  $30.87M
                  8
                  Amundi Index MSCI USA SRI PAB -UCITS ETF DR C- Capitalisation
                  $13.24M
                  8
                  iShares U.S. Pharmaceuticals ETF
                  $11.95M
                  8
                  VanEck Pharmaceutical ETF
                  $8.91M
                  8
                  iShares Core S&P Total U.S. Stock Market ETF
                  $8.46M
                  8
                  Up to five ETFs with an Outperform Smart Score that hold JAZZ. The ETFs are listed according to market value of JAZZ within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  ACADIA Pharmaceuticals
                  Biogen
                  Incyte
                  Ionis Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis